NGEN (NervGen Pharma) Other Current Liabilities: $0.00 Mil (As of Mar. 2026)


NGEN NervGen Pharma Corp NGEN
22 GF Score
Price $2.10
! 2 Warning Signs
View Full Analysis

What is NervGen Pharma Other Current Liabilities?

NervGen Pharma NGEN +1.44% 22 Other Current Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates NGEN with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

NervGen Pharma's other current liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

NervGen Pharma's quarterly other current liabilities increased from Sep. 2025 ($8.39 Mil) to Dec. 2025 ($11.91 Mil) but then declined from Dec. 2025 ($11.91 Mil) to Mar. 2026 ($0.00 Mil).

NervGen Pharma's annual other current liabilities declined from Dec. 2023 ($9.32 Mil) to Dec. 2024 ($9.14 Mil) but then increased from Dec. 2024 ($9.14 Mil) to Dec. 2025 ($11.91 Mil).

NervGen Pharma Other Current Liabilities Related Terms

NervGen Pharma Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for NervGen Pharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma Other Current Liabilities Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only 0.00 4.96 9.32 9.14 11.91

NervGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.32 9.97 8.39 11.91 0.00
NGEN
22GF Score
NervGen Pharma Corp NGEN
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NervGen Pharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.00 Mil mean?
NervGen Pharma (NGEN) has a Other Current Liabilities of $0.00 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on NervGen Pharma.
Is NervGen Pharma's Other Current Liabilities too high?
NervGen Pharma's current Other Current Liabilities is $0.00 Mil. Overall, NervGen Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does NervGen Pharma's Other Current Liabilities compare to NKTX and UNCY?
NervGen Pharma's Other Current Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on NervGen Pharma. NervGen Pharma's current Other Current Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NervGen Pharma stock overvalued right now?
NervGen Pharma (NGEN) has a current Other Current Liabilities of $0.00 Mil. The current Other Current Liabilities is $0.00 Mil. NervGen Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For NervGen Pharma (NGEN), the current Other Current Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NervGen Pharma Business Description

Other Exchanges 9UA:Germany
Address 112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
22GF Score

Get the complete analysis for NGEN

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price